New GLP-1 Products in 2026: The Telehealth Product Map

2026 is the year GLP-1 care becomes a product map

For the last few years, many telehealth teams treated GLP-1 care as one broad funnel:

patient wants weight loss, patient completes intake, provider reviews, pharmacy fulfills, support helps with refills.

That is no longer enough.

In 2026, GLP-1 care is becoming a product map.

The category now includes:

weekly injectable products
daily oral products
higher-dose semaglutide
direct-access and self-pay pharmacy paths
approved obesity indications tied to comorbidities
investigational combination and triple-agonist products
tighter FDA scrutiny around compounded GLP-1 workflows

For DTC telehealth teams, the practical question is not only "which medication is available?"

The better question is:

"Which product pathway can we explain, prescribe, bill, fulfill, support, and monitor clearly?"

That is where most programs will either win trust or create confusion.

The May 2026 GLP-1 product map

The first step is to separate commercial reality from pipeline excitement.

As of May 20, 2026, the operator view looks like this:

Product or pathway	Status	Why it matters for telehealth
Wegovy tablet	FDA-approved oral semaglutide tablet for chronic weight management	Creates a daily oral workflow instead of weekly injection-only support
Wegovy HD	FDA-approved 7.2 mg semaglutide injection as of March 19, 2026	Adds a higher-dose pathway that needs careful patient selection and education
Foundayo / orforglipron	FDA-approved oral GLP-1 as of April 1, 2026 and available in the U.S. as of April 9, 2026	Gives patients another oral option with a different adherence and access story
Zepbound	Existing approved tirzepatide pathway with expanding access and self-pay relevance	Remains a core comparison point for patient expectations and pricing questions
CagriSema	FDA submission filed in December 2025; decision expected later in 2026	Could create a combination-injection pathway, but is not a launchable offer yet
Retatrutide	Investigational Phase 3 triple agonist; not FDA-approved	High patient curiosity, but should stay in education and support readiness
Survodutide	Investigational glucagon/GLP-1 dual agonist with 2026 Phase 3 data; not FDA-approved	Signals a broader metabolic-health future, not current DTC availability

That table should influence more than content strategy.

It should shape how your platform handles intake, product education, provider review, payment, pharmacy status, refills, and support scripts.

Treatments

Example GLP-1 Treatments We Can Launch

View all

What is actually new in 2026

Several changes are easy to blur together.

They should be separated.

1. Oral GLP-1s are now commercial, not just pipeline

The biggest change is that oral GLP-1 options are now part of the weight-management conversation.

FDA materials show Wegovy tablets as an oral semaglutide option for weight management, and the Wegovy tablet label includes oral dosing instructions. Lilly's Foundayo, orforglipron, was approved by FDA on April 1, 2026 and Lilly announced U.S. availability on April 9, 2026.

Foundayo is especially important operationally because Lilly describes it as a once-daily pill that can be taken without food or water restrictions. That is a different patient education flow from oral semaglutide products that require more specific administration timing.

For telehealth teams, this means "oral GLP-1" cannot be one generic label.

Different oral products can have different:

timing instructions
adherence risks
refill cadence
pricing paths
insurance and self-pay expectations
pharmacy distribution models
patient support needs

2. Higher-dose semaglutide adds a new patient-selection layer

On March 19, 2026, FDA approved Wegovy HD, a 7.2 mg semaglutide injection for weight loss and long-term maintenance of weight loss in certain adult patients.

This is not just another SKU.

Higher-dose pathways change the operational conversation around:

who may be appropriate for escalation
how prior therapy is documented
how side-effect history is reviewed
how patient expectations are set
how provider review distinguishes standard start, continuation, switch, and escalation
how support handles dose questions without giving clinical advice

Telehealth teams should avoid presenting higher-dose options as "stronger is better."

The workflow should make clear that medication selection and dose decisions belong to licensed provider review.

3. Pipeline products are getting more attention before approval

CagriSema, retatrutide, and survodutide are attracting patient and investor attention.

That does not mean they belong in checkout.

CagriSema is a combination of semaglutide and the amylin analogue cagrilintide. Novo Nordisk has disclosed a U.S. filing and an expected 2026 regulatory milestone, but the product should be treated as a potential future pathway until approval, label, pricing, access, and distribution are real.

Retatrutide is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. Lilly has reported Phase 3 results, including obesity and type 2 diabetes data, but it is not FDA-approved as of this post date.

Survodutide is an investigational glucagon/GLP-1 dual agonist. Boehringer Ingelheim announced positive Phase 3 obesity data in April 2026, but it is also not a commercial DTC telehealth product today.

The marketing lesson is simple:

education is fine.

availability claims are not.

The compounding environment is moving in the opposite direction

While product choice is expanding on the approved side, FDA scrutiny is increasing around compounded GLP-1s.

On April 1, 2026, FDA clarified its policies for compounders as GLP-1 supply stabilizes. FDA reminded compounders that compounded drugs must meet the conditions of section 503A or 503B of the FD&C Act, and that products can be considered essentially copies of commercially available drugs under certain conditions.

Then on April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, saying it did not identify a clinical need for outsourcing facilities to compound those drugs from bulk drug substances.

For DTC telehealth teams, this changes the risk profile.

The 2024 and 2025 playbook of "use compounded GLP-1s as the broad workaround" is not a stable product strategy in 2026.

Teams need to be precise about:

whether a product is FDA-approved
whether a product is compounded
whether the compounder is 503A or 503B
whether the medication is on the shortage list at the relevant time
whether the copy rules are implicated
whether marketing language implies equivalence to approved products
whether patients understand what they are receiving

Helpful FDA references include FDA's April 1 compounded GLP-1 policy clarification and FDA's April 30 503B bulks-list proposal.

Product choice should change intake

New products make intake more important, not less.

The intake should help providers understand:

whether the patient is starting, continuing, switching, or restarting therapy
whether the patient prefers oral or injectable options
whether the patient has used semaglutide, tirzepatide, liraglutide, or another related therapy before
what side effects or tolerability issues the patient has experienced
whether the patient has obesity alone or weight-related comorbidities
whether the patient is using insurance, self-pay, or hybrid payment paths
whether the patient has a pharmacy preference
whether labs, vitals, or other monitoring are needed
whether the patient is asking about investigational or non-approved products

The goal is not to let the patient self-select a medication from a menu.

The goal is to collect enough structured information for responsible routing and provider review.

Product choice should change patient education

The patient-facing education layer needs to get more specific.

A single "GLP-1 medication guide" is no longer enough for every pathway.

Patients may need separate education for:

weekly injection workflows
daily oral workflows
administration timing
storage and handling
dose escalation
missed doses
switching from another therapy
cost and coverage differences
pharmacy pickup versus home delivery
refill timing
side effects and when to contact the care team
pipeline products that are not available yet

Patient education should also avoid ranking products in a way that sounds like consumer electronics.

There is no universal "best GLP-1."

There is a best-fit care path based on eligibility, clinical context, access, affordability, tolerability, and provider judgment.

Product choice should change billing and access UX

New GLP-1 products also change the checkout and billing layer.

Before payment, patients should understand:

whether provider review is required
whether medication is included
whether the medication is branded, compounded, or pharmacy-filled
whether insurance, self-pay, or manufacturer access may apply
whether the monthly price changes by dose or product
whether the first payment is refundable if treatment is not approved
whether shipping or pharmacy pickup is included
whether refills are automatic or require review
how price changes are communicated

This is where many GLP-1 programs create avoidable churn.

Patients are comparing price, product, access, and support at the same time.

If those pieces are split across the landing page, checkout, provider message, and pharmacy email, trust gets thin fast.

Product choice should change support scripts

Support teams will hear the product map before leadership dashboards do.

Patients will ask:

Is the pill the same as the shot?
Is Foundayo better than Wegovy?
Can I switch from Zepbound?
Is Wegovy HD for faster results?
Can I get retatrutide?
When will CagriSema be available?
Is compounded semaglutide still legal?
Why is one product cheaper than another?
Can I choose the medication myself?

Those questions need approved answers.

Support should know which questions are administrative, which are educational, and which require provider review.

The rule of thumb:

support can explain workflow, status, billing, and next steps.

Providers own clinical appropriateness, medication selection, dose changes, and safety concerns.

A practical 2026 GLP-1 product strategy

For a DTC telehealth team, the best product strategy is usually staged.

Stage 1: Clean up the current approved pathways

Make sure standard injectable and supported oral options are clearly represented in intake, education, billing, pharmacy, refill, and support workflows.

Stage 2: Add product-aware routing

Do not ask patients only whether they want GLP-1 treatment.

Capture whether they are new, switching, restarting, injection-averse, cost-sensitive, coverage-dependent, or looking for maintenance.

Stage 3: Separate pipeline education from commercial offers

Write about CagriSema, retatrutide, survodutide, and other pipeline names only as watchlist items unless and until approval and access are real.

Stage 4: Rebuild compounded-product governance

If compounded GLP-1s are still part of the model, review the workflow against FDA's 2026 policy posture, marketing language, pharmacy sourcing, and patient-facing disclosures.

Stage 5: Measure product complexity

Track whether new product options improve conversion and retention or simply increase confusion.

Useful metrics include:

intake completion by product interest
provider review time by pathway
support tickets by product name
oral versus injectable adherence questions
switch requests
refill delays by product path
pharmacy exceptions
refund reasons tied to access or price confusion
month-two retention by product path

Final takeaways

New GLP-1 products in 2026 are not just adding more names to the category.

They are changing the operating model.

The teams that handle this well will:

separate approved products from investigational products
explain oral, injectable, and higher-dose pathways clearly
keep medication decisions inside provider review
update intake around product-aware routing
make billing and access visible before checkout
give support teams clear scripts for pipeline and compounding questions
keep patient education specific to the actual pathway
treat FDA compounding scrutiny as a product-strategy constraint, not a footnote

The category is becoming more powerful, more segmented, and more consumer-facing.

That creates opportunity for DTC telehealth.

It also raises the bar.

In 2026, the strongest GLP-1 programs will not be the ones with the longest medication list.

They will be the ones that make the right product path feel understandable, clinically grounded, and operationally reliable.